Evry, France-Neurotech will refocus its efforts on ophthalmic technologies, halting research and development activities in the fields of neuroscience and cell therapy.
enGene Snags FDA RMAT Designation for Bladder Cancer Gene Therapy Detalimogene
The gene therapy is currently being evaluated in the phase 1/2 LEGEND clinical trial.
Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead
Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Rajesh Pahwa, MD.
FDA Announces Investigation of Deaths Following Treatment With Sarepta’s DMD Gene Therapy Elevidys
The FDA stated that it is assessing the risk of ALF that results in hospitalization or death after treatment and whether additional regulatory measures will be necessary.
ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP
In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.
Zhengzhou Revo-Gene Technology Assesses DC-CTL Cells for the Treatment of Solid Tumors in Real World Exploratory Study
The study, which may enroll from 20 to 200 participants in total, will administer the DC-CTL cells 1 to 2 days after the patients have received conventional antitumor therapy.
Exploring DARIC CAR T Cells for Autoimmune Indications
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute, discussed preclinical work on using dimerizing agent-regulated immune-receptor complex T-cells to target plasma cells.